If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ™ (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
When will Zepbound™ (tirzepatide) be available?
Zepbound was FDA approved on November 8, 2023 and will be available in the U.S. by the end of the year.
See important safety information, including boxed warning, in the attached prescribing information.
Availability
Zepbound was FDA approved on November 8, 2023.1
Zepbound is expected to be available in the U.S. by the end of the year in six dosage strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg).1
Enclosed Prescribing Information
Reference
1Zepbound Press Release. FDA approves Lilly's Zepbound™ (tirzepatide) for chronic weight management, a powerful new option for the treatment of obesity or overweight with weight-related medical problems. Press release. Eli Lilly and Company; November 8, 2023. Accessed November 8, 2023. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight
Date of Last Review: November 08, 2023